The review of our CDP plan was positive and noted that the "potential candidates described were very strong." However, our reliance on a funding source for senior level post-doctoral fellows was considered "not consistent with the SPORE guidelines." We have therefore revised the entire CDP to more cleariy provide research support for advanced fellows, junior faculty and established investigators who wish to develop or refocus their careers on translational breast cancer research. CDP support for research fellows through the Thomsen Family Fellowship will be used only when it is for support of research fellows transitioning to independent faculty appointments. In this submission, we have clarified our goals and our adherence to the SPORE guidelines. Our proposed plan describes in detail how promising individuals with an interest in, and expressed commitment to, translational breast cancer research will be selected. It further addresses how the CDP leadership will seek out and recruit qualified women and minorities for participation in the program. More specifically, the CDP Leadership will use program funds to recruit and nurture qualified investigators at all levels. CDP leaders will provide a system for mentoring such individuals in a broad range of disciplines and create a framework in which investigators can gain exposure to, and possibly training in, aspects of translational breast cancer research outside their areas of expertise. Ensuring that innovative ideas can develop into promising translational studies in breast cancer research, and that women, minorities and developing faculty who can make key contributions to translational breast cancer research at the FHCRC and UW, are strongly recruited and retained are also key goals ofthe current plan. In a response to the comment: "Although the commitment to diversity is not questioned, a paragraph stating the gender/minority composition ofthe research programs at FHCRC/UW was not included", we have added two tables to section C.2 to address this oversight. The first presents the ethnic breakdown of faculty, postdoctoral candidates and pre-doctoral students at FHCRC as of December 31, 2008. The second provides enrollment figures by ethnicity for the UW School of Medicine (UWSOM) in 2007.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
Berger, Carolina; Sommermeyer, Daniel; Hudecek, Michael et al. (2015) Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. Cancer Immunol Res 3:206-16
Stephan, Sirkka B; Taber, Alexandria M; Jileaeva, Ilona et al. (2015) Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat Biotechnol 33:97-101
Jensen, Michael C; Riddell, Stanley R (2014) Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev 257:127-44
Marcondes, A Mario; Karoopongse, Ekapun; Lesnikova, Marina et al. (2014) ?-1-Antitrypsin (AAT)-modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics. Blood 124:2881-91
Partridge, Savannah C; Stone, Karen M; Strigel, Roberta M et al. (2014) Breast DCE-MRI: influence of postcontrast timing on automated lesion kinetics assessments and discrimination of benign and malignant lesions. Acad Radiol 21:1195-203
Riddell, Stanley R; Sommermeyer, Daniel; Berger, Carolina et al. (2014) Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition. Cancer J 20:141-4
Kennedy, Jacob J; Abbatiello, Susan E; Kim, Kyunggon et al. (2014) Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Nat Methods 11:149-55
Hudecek, Michael; Lupo-Stanghellini, Maria-Teresa; Kosasih, Paula L et al. (2013) Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res 19:3153-64
Sun, Jianping; Zheng, Yingye; Hsu, Li (2013) A unified mixed-effects model for rare-variant association in sequencing studies. Genet Epidemiol 37:334-44
Qu, Xiaoyu; Randhawa, Grace; Friedman, Cynthia et al. (2013) A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors. PLoS One 8:e74671

Showing the most recent 10 out of 14 publications